COVID-19 Drug-Screening and Resistance Hub (CRUSH)
COVID-19 Drug-Screening and Resistance Hub (CRUSH)
We have developed a fully integrated hub for SARSCoV-2 drug screening and resistance assays in tissue culture and pre-clinical animal models called the COVID-19 Drug-Screening and Resistance Hub (CRUSH). CRUSH also supports other research needs arising as a result of the COVID-19 pandemic including, for example, vaccine efficacy in pre-clinical animal models, the validation of virus inactivating buffers for downstream diagnostic assays and the development of viruses by reverse genetics. CRUSH activities have and will continue to focus on SARS-CoV-2, but the longer-term goal is to create a stable and sustainable resource for the UK that will help to accelerate drug discovery for any known or novel high consequence virus requiring high containment facilities at either Category Level 3 (CL3) or CL2.
Key contact: Claire Macdonald (CRSUH Buisness Development and Liaison Manager): Claire.MacDonald.2@glasgow.ac.uk
Key contact: Agnieszka Szemiel (CRUSH Facility Manager): Agnieszka.Szemiel@glasgow.ac.uk